ClinicalTrials.gg
CompletedNCT01734993Updated Nov 28, 2016Results posted

A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).

A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
106th of 110
11 · median 97
Started
2012
with 10 others
Phase 3
65 of 110
none open now
Registered
70th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 106th largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 70th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This multicenter, open-label, single arm, interventional, long-term extension (LTE) study will evaluate the safety and efficacy of tocilizumab (TCZ, RoActemra/Actemra) in French participants with moderate to severe RA who have completed the Week 97 visit of WA22762 LTE study (NCT01194414) (EudraCT Number 2010-018375-22). Participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in disease activity score based on 28-joint count [DAS28] of greater than [>] 1.2 points) will continue TCZ treatment within this local LTE study for a maximum of 156 weeks of subcutaneous (SC) TCZ treatment, or until SC TCZ becomes commercially available, whichever occurs first.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Negative pregnancy test at screening and baseline
  • Participants who have completed the 97-week WA22762 LTE study on SC or intravenous (IV) TCZ and who experienced, at any time during WA22762, improvement in DAS28 (>1.2 points), and based on the investigator's judgment may continue to benefit from TCZ treatment in this study investigating the SC formulation
  • No current or recent adverse events or laboratory findings preventing the use of the study drug dose of TCZ 162 mg SC at baseline visit
  • Receiving treatment on an outpatient basis
  • Females of and males with female partners of childbearing potential must agree to use reliable means of during the study and for at least 3 months following the last dose of study drug
  • Oral and non-steroidal anti-inflammatory drugs (NSAIDS) up to the recommended dose are permitted if on stable dose regimen for greater than and equal to (>/=) 4 weeks prior to baseline
  • Permitted non-biological disease-modifying anti-rheumatic drugs (DMARDs) are allowed

Exclusion criteria

Exclusion Criteria:

  • Participants who have prematurely withdrawn from the WA22762 LTE study for any reason
  • Previous treatment with any cell-depleting therapies, including agents or approved therapies
  • Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL) 1 agent, or a T-cell co stimulation modulator since the last administration of study drug in the WA22762 LTE study
  • Immunization with a live/attenuated vaccine since the last administration of study drug in the WA22762 LTE study
  • Diagnosis, since last WA22762 visit (Week 97), of rheumatic disease other than rheumatoid arthritis; secondary Sjörgen's syndrome with RA is permitted
  • Diagnosis, since last WA22762 visit (Week 97), of inflammatory joint disease other than RA
  • Uncontrolled disease states, such as asthma or inflammatory bowel disease, where flares are commonly treated with oral or parenteral
  • Evidence of serious uncontrolled concomitant disease
  • Known active current or history of recurrent infection
  • Primary or secondary immunodeficiency (history of or currently active)
  • Body weight >150 kilograms (kg)
  • Pregnant or lactating women
  • Inadequate hematologic, renal or liver function
  • History of alcohol, drug or chemical abuse within 1 year prior to screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Moderate to severe rheumatoid arthritis participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in DAS28 of \>1.2 points) will continue tocilizumab treatment within this local LTE study for a maximum of 156 weeks, or until SC TCZ becomes commercially available, whichever occurs first.

    Drug: Tocilizumab

Interventions

  • Participants will receive TCZ 162 milligrams (mg) SC injection once a week.

    Also known as: RoActemra, Actemra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who was administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment. A SAE was any untoward medical occurrence that at any dose resulted in death, was life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity, and congenital anomaly/birth defect. AEs included SAEs as well as non-serious AEs.

    Time frame: Baseline up to approximately 142 weeks

  2. Percentage of Participants With AEs and SAEs Related to TCZ

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included SAEs as well as non-serious AEs. Causality of AEs based on physician's discretion: certain (AE after drug intake, not explained by other drugs, reaction on drug cessation \[DC\], relapse on re-intake of drug), probable/likely (AE after drug intake, not explained by other drugs, reaction on DC, no information on re-intake), possible (AE after drug intake, explained by other drugs, no information on DC), unlikely (not related to drug intake time, explained by other drugs). AEs with causality of certain, probable/likely, and possible were considered TCZ related.

    Time frame: Baseline up to approximately 142 weeks

  3. Percentage of Participants With Adverse Events of Special Interest (AESIs)

    Adverse events of special interest (AESI) for this study included: infections (including opportunistic infections), myocardial infarction/acute coronary syndrome, gastrointestinal perforation and related events, malignancies, anaphylaxis / hypersensitivity reactions, demyelinating disorders, stroke, bleeding events and hepatic events.

    Time frame: Baseline up to approximately 142 weeks

  4. Percentage of Participants With AESIs Related to TCZ

    AESI for this study included: infections (including opportunistic infections), myocardial infarction/acute coronary syndrome, gastrointestinal perforation and related events, malignancies, anaphylaxis / hypersensitivity reactions, demyelinating disorders, stroke, bleeding events and hepatic events. Percentage of participants with AESI related to the drug were presented. Causality of AESIs based on physician's discretion: certain (AE after drug intake, not explained by other drugs, reaction on DC, relapse on re-intake of drug), probable/likely (AE after drug intake, not explained by other drugs, reaction on DC, no information on re-intake), possible (AE after drug intake, explained by other drugs, no information on DC), unlikely (not related to drug intake time, explained by other drugs). AESIs with causality of certain, probable/likely, and possible were considered TCZ related.

    Time frame: Baseline up to approximately 142 weeks

  5. Percentage of Participants With AEs Leading to TCZ Discontinuation, Interruption, or Dose Modification

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Percentage of participants with AE causing drug discontinuation, interruption and increase or decrease in dose of drug was presented.

    Time frame: Baseline up to approximately 142 weeks

  6. Percentage of Participants With Clinically Significant Physical Examinations and Vital Signs Abnormalities

    Criteria for potentially clinically important (PCI) change in vital signs: heart rate value of less than (\<) 40 beats per minute and value greater than (\>) 150 beats per minute, systolic blood pressure (SBP) of \< 80 or \>210 millimeter of mercury (mmHg), diastolic blood pressure (DBP) of \<40 or \>130 mmHg, body temperature \<32 or \> 40 degrees Celsius, respiratory rate of \<10 or \> 50 breaths/minute and criteria for PCI change in physical examination: \>/=10% increase or decrease of body weight in kilograms (kg).

    Time frame: Baseline up to approximately 142 weeks

  7. Percentage of Participants With Clinically Significant Laboratory Abnormalities

    Criteria for laboratory tests clinically significant abnormalities included: hemoglobin, hematocrit and red blood cells (RBCs)(\< 0.8\*lower limit of normal\[LLN\]); leucocytes (\<0.6/greater than \[\>\]1.5\*upper limit of normal \[ULN\]); platelets (\<0.5\*LLN\>\</0\>1.75\*ULN); neutrophils, lymphocytes (\<0.8\*LLN\>\</0\>1.2\*ULN); eosinophils, basophils, monocytes (\>1.2\*ULN); total bilirubin, direct bilirubin, indirect bilirubin (\>1.5\*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (\>3\*ULN), total protein, albumin (\<0.8\*LLN\>\</0\>1.2\*ULN); creatinine, urea (\>1.3\*ULN); glucose (\<0.6\*LLN\>\</0\>1.5\*ULN); uric acid (\>1.2\*ULN); sodium, potassium, chloride, calcium, bicarbonate (\<0.9\*LLN\>\</0\>1.1\*ULN); urine RBCs, urine white blood cells (WBCs) (\> or equal\[=\]20 high-powered field), urine bacteria \>20 high-powered field. Overall percentage of participants with any clinically significant laboratory abnormality was reported.

    Time frame: Baseline up to approximately 142 weeks

  8. Percentage of Participants With Anti-TCZ Antibodies

    Time frame: Baseline up to approximately 142 weeks

Secondary outcomes

  1. Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score

    The DAS 28 ESR score is a measure of the participant's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment (PtGA) of disease activity (visual analog scale \[VAS\]: 0 millimeter \[mm\] = no disease activity to 100 mm=maximum disease activity) and the erythrocyte sedimentation rate (ESR in millimeters per hour \[mm/hr\]). DAS28 was calculated using following formulas: DAS28-ESR = 0.56\*square root (sqrt) (TJC28) + 0.28\*sqrt (SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*PtGA of disease activity. A total possible score of 0 to approximately 10, with higher score indicating more severe disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

    Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)

  2. Change From Baseline in Simplified Disease Activity Index (SDAI) Score

    The SDAI was calculated as (SJC \[28 joints\] + TJC \[28 joints\] + VAS ptGA + VAS physician global assessment of disease activity + C-reactive Protein (CRP) level in milligram/deciliter \[mg/dL\]). VAS assessments: 0 centimeters (cm)=no disease activity to 10 cm=maximum disease activity. SDAI score ranged from 0 to 86, with higher scores indicating increased disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

    Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)

  3. Change From Baseline in TJC

    For TJC a total of 28 joints were assessed. The presence of a tender joint was scored as 1 and absence as 0. Total score is calculated by adding the scores, which is ranging from 0 (best possible score or no tender joint) to 28 (worse possible score or all tender joints). Lower scores indicate no tender joint and higher scores indicate worsening tender joints. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

    Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)

  4. Change From Baseline in SJC

    For SJC, a total of 28 joints were assessed. The presence of a swollen joint was scored as 1 and absence as 0. Total score is calculated by adding the scores, which is ranging from 0 (best possible score or no swollen joint) to 28 (worse possible score or all swollen joints). Lower scores indicate no swollen joint and higher scores indicate worsening swollen joints. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

    Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)

  5. Percentage of Participants With Clinical Remission

    Clinical remission defined as:DAS28-ESR score \< 2.6 and/or SDAI score \</= 3.3.DAS28 score is measure of subject's disease activity calculated using TJC \[28 joints\],SJC \[28 joints\],PtGA of disease activity \[ VAS:0mm= no disease activity to 100 mm=maximum disease activity\] and ESR (mm/hr). DAS28 was calculated as DAS28-ESR = 0.56\*sqrt (TJC28) + 0.28\*sqrt(SJC28) + 0.70\* ln ESR + 0.014\*PtGA of disease activity. DAS28-ESR score ranged from 0 to approximately 10, higher score indicating more severe disease activity. SDAI was calculated =\[SJC (28 joints) + TJC (28 joints) + VAS PtGA + VAS physician global assessment of disease activity+CRP level(mg/dL)\]. VAS assessments:0 mm=no disease activity to 100 mm=maximum disease activity. SDAI score ranged from 0 to 86, with higher scores indicating increased disease activity.

    Time frame: Week 48, 108

  6. Percentage of Participants With Concomitant Corticosteroid Discontinuation

    Time frame: Baseline up to approximately 142 weeks

  7. Percentage of Participants With Concomitant Corticosteroid Dose Reduction

    Time frame: Baseline up to approximately 142 weeks

  8. Time to Concomitant Corticosteroid Discontinuation

    Time to corticosteroid discontinuation = (End date of corticosteroid treatment - date of first drug intake of this extension study) + 1.

    Time frame: Baseline up to approximately 142 weeks

  9. Time to Concomitant Corticosteroid Dose Reduction

    Time to corticosteroid dose reduction (days) = (Date of the first dose reduction of corticosteroid treatment - date of first drug intake of this extension study) + 1.

    Time frame: Baseline up to approximately 142 weeks

  10. Change From Baseline in PtGA of Disease Activity

    PtGA of disease activity over the previous 24 hours using a 100 mm VAS where left end of the line 0 mm =no disease activity and right end of the line 100 mm =maximum disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

    Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)

  11. Change From Baseline in Patient's Assessment of Pain

    Patient's assessment of pain over the previous 24 hours: using a VAS, left end of the line 0 mm=no pain to right end of the line 100 mm=unbearable pain. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

    Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)

  12. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score

    The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

    Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)

  13. Change From Baseline in Physician's Global Assessment of Disease Activity

    The Physician's Global Assessment of disease activity was assessed using a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity". Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

    Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)

  14. Change From Baseline in ESR

    Blood samples were collected for ESR, which is an acute phase reactant and provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeters per hour (mm/hr). A decrease in the level indicates reduction in inflammation and therefore improvement. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

    Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)

  15. Change From Baseline in CRP

    Blood samples were collected for CRP, which is an acute phase reactant and a measure of inflammation. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

    Time frame: Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)

07

Results

Posted Nov 28, 2016

Participant flow

A total of 12 participants were screened at 6 sites in France, of which 11 participants were enrolled.

Participant flow — Overall Study
MilestoneTocilizumab
Started11
Completed9
Not completed2
Withdrew: Adverse event1
Withdrew: Lack of efficacy1

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who was administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment. A SAE was any untoward medical occurrence that at any dose resulted in death, was life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity, and congenital anomaly/birth defect. AEs included SAEs as well as non-serious AEs.

Time frame:
Baseline up to approximately 142 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of participantsTocilizumab
Any AE100
SAE18.2
PrimaryPercentage of Participants With AEs and SAEs Related to TCZ

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included SAEs as well as non-serious AEs. Causality of AEs based on physician's discretion: certain (AE after drug intake, not explained by other drugs, reaction on drug cessation \[DC\], relapse on re-intake of drug), probable/likely (AE after drug intake, not explained by other drugs, reaction on DC, no information on re-intake), possible (AE after drug intake, explained by other drugs, no information on DC), unlikely (not related to drug intake time, explained by other drugs). AEs with causality of certain, probable/likely, and possible were considered TCZ related.

Time frame:
Baseline up to approximately 142 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs and SAEs Related to TCZ
Percentage of participantsTocilizumab
Related AE72.7
Related SAE9.1
PrimaryPercentage of Participants With Adverse Events of Special Interest (AESIs)

Adverse events of special interest (AESI) for this study included: infections (including opportunistic infections), myocardial infarction/acute coronary syndrome, gastrointestinal perforation and related events, malignancies, anaphylaxis / hypersensitivity reactions, demyelinating disorders, stroke, bleeding events and hepatic events.

Time frame:
Baseline up to approximately 142 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events of Special Interest (AESIs)
Percentage of participantsTocilizumab
Percentage of Participants With Adverse Events of Special Interest (AESIs)18.2
PrimaryPercentage of Participants With AESIs Related to TCZ

AESI for this study included: infections (including opportunistic infections), myocardial infarction/acute coronary syndrome, gastrointestinal perforation and related events, malignancies, anaphylaxis / hypersensitivity reactions, demyelinating disorders, stroke, bleeding events and hepatic events. Percentage of participants with AESI related to the drug were presented. Causality of AESIs based on physician's discretion: certain (AE after drug intake, not explained by other drugs, reaction on DC, relapse on re-intake of drug), probable/likely (AE after drug intake, not explained by other drugs, reaction on DC, no information on re-intake), possible (AE after drug intake, explained by other drugs, no information on DC), unlikely (not related to drug intake time, explained by other drugs). AESIs with causality of certain, probable/likely, and possible were considered TCZ related.

Time frame:
Baseline up to approximately 142 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With AESIs Related to TCZ
Percentage of participantsTocilizumab
Percentage of Participants With AESIs Related to TCZ18.2
PrimaryPercentage of Participants With AEs Leading to TCZ Discontinuation, Interruption, or Dose Modification

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Percentage of participants with AE causing drug discontinuation, interruption and increase or decrease in dose of drug was presented.

Time frame:
Baseline up to approximately 142 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs Leading to TCZ Discontinuation, Interruption, or Dose Modification
Percentage of participantsTocilizumab
AE Leading to Discontinuation9.1
AE Leading to Interruption63.6
AE Leading to Dose Modification0.0
PrimaryPercentage of Participants With Clinically Significant Physical Examinations and Vital Signs Abnormalities

Criteria for potentially clinically important (PCI) change in vital signs: heart rate value of less than (\<) 40 beats per minute and value greater than (\>) 150 beats per minute, systolic blood pressure (SBP) of \< 80 or \>210 millimeter of mercury (mmHg), diastolic blood pressure (DBP) of \<40 or \>130 mmHg, body temperature \<32 or \> 40 degrees Celsius, respiratory rate of \<10 or \> 50 breaths/minute and criteria for PCI change in physical examination: \>/=10% increase or decrease of body weight in kilograms (kg).

Time frame:
Baseline up to approximately 142 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Significant Physical Examinations and Vital Signs Abnormalities
Percentage of participantsTocilizumab
Percentage of Participants With Clinically Significant Physical Examinations and Vital Signs Abnormalities0.0
PrimaryPercentage of Participants With Clinically Significant Laboratory Abnormalities

Criteria for laboratory tests clinically significant abnormalities included: hemoglobin, hematocrit and red blood cells (RBCs)(\< 0.8\*lower limit of normal\[LLN\]); leucocytes (\<0.6/greater than \[\>\]1.5\*upper limit of normal \[ULN\]); platelets (\<0.5\*LLN\>\</0\>1.75\*ULN); neutrophils, lymphocytes (\<0.8\*LLN\>\</0\>1.2\*ULN); eosinophils, basophils, monocytes (\>1.2\*ULN); total bilirubin, direct bilirubin, indirect bilirubin (\>1.5\*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (\>3\*ULN), total protein, albumin (\<0.8\*LLN\>\</0\>1.2\*ULN); creatinine, urea (\>1.3\*ULN); glucose (\<0.6\*LLN\>\</0\>1.5\*ULN); uric acid (\>1.2\*ULN); sodium, potassium, chloride, calcium, bicarbonate (\<0.9\*LLN\>\</0\>1.1\*ULN); urine RBCs, urine white blood cells (WBCs) (\> or equal\[=\]20 high-powered field), urine bacteria \>20 high-powered field. Overall percentage of participants with any clinically significant laboratory abnormality was reported.

Time frame:
Baseline up to approximately 142 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Significant Laboratory Abnormalities
Percentage of participantsTocilizumab
Percentage of Participants With Clinically Significant Laboratory Abnormalities9.1
PrimaryPercentage of Participants With Anti-TCZ Antibodies
Time frame:
Baseline up to approximately 142 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-TCZ Antibodies
Percentage of participantsTocilizumab
Percentage of Participants With Anti-TCZ Antibodies0.0
SecondaryChange From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score

The DAS 28 ESR score is a measure of the participant's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment (PtGA) of disease activity (visual analog scale \[VAS\]: 0 millimeter \[mm\] = no disease activity to 100 mm=maximum disease activity) and the erythrocyte sedimentation rate (ESR in millimeters per hour \[mm/hr\]). DAS28 was calculated using following formulas: DAS28-ESR = 0.56\*square root (sqrt) (TJC28) + 0.28\*sqrt (SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*PtGA of disease activity. A total possible score of 0 to approximately 10, with higher score indicating more severe disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

Time frame:
Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Reported as:
Mean · Units on a scale
Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score
Units on a scaleTocilizumab
Baseline (n=11)1.81 ± 0.87
Change at Week 12 (n=8)0.16 ± 1.59
Change at Week 24 (n=9)-0.14 ± 1.17
Change at Week 36 (n=9)-0.02 ± 1.30
Change at Week 48 (n=10)-0.32 ± 0.93
Change at Week 60 (n=10)-0.33 ± 1.14
Change at Week 72 (n=10)-0.35 ± 0.92
Change at Week 84 (n=9)0.28 ± 1.23
Change at Week 96 (n=9)-0.36 ± 1.11
Change at Week 108 (n=7)-0.14 ± 1.55
Change at Week 120 (n=2)-0.75 ± 0.88
Change at Completer last visit (n=9)-0.16 ± 1.19
Change at Early withdrawal (n=2)2.76 ± 0.87
Change at Last visit (n=11)0.38 ± 1.61
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) Score

The SDAI was calculated as (SJC \[28 joints\] + TJC \[28 joints\] + VAS ptGA + VAS physician global assessment of disease activity + C-reactive Protein (CRP) level in milligram/deciliter \[mg/dL\]). VAS assessments: 0 centimeters (cm)=no disease activity to 10 cm=maximum disease activity. SDAI score ranged from 0 to 86, with higher scores indicating increased disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

Time frame:
Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Reported as:
Mean · Units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) Score
Units on a scaleTocilizumab
Baseline (n=5)7.21 ± 4.15
Change at Week 12 (n=5)9.17 ± 12.63
Change at Week 24 (n=2)8.48 ± 7.81
Change at Week 36 (n=3)4.50 ± 4.61
Change at Week 48 (n=2)-1.02 ± 0.23
Change at Week 60 (n=2)-1.02 ± 1.32
Change at Week 72 (n=3)4.19 ± 1.66
Change at Week 84 (n=3)0.83 ± 3.43
Change at Week 96 (n=3)0.60 ± 4.95
Change at Week 108 (n=3)5.25 ± 8.15
Change at Week 120 (n=0)NA ± NA
Change at Completer last visit (n=2)0.69 ± 5.02
Change at Early withdrawal (n=1)17.38 ± NA
Change at Last visit (n=3)6.25 ± 10.27
SecondaryChange From Baseline in TJC

For TJC a total of 28 joints were assessed. The presence of a tender joint was scored as 1 and absence as 0. Total score is calculated by adding the scores, which is ranging from 0 (best possible score or no tender joint) to 28 (worse possible score or all tender joints). Lower scores indicate no tender joint and higher scores indicate worsening tender joints. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

Time frame:
Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Reported as:
Mean · Tender Joints
Change From Baseline in TJC
Tender JointsTocilizumab
Baseline (n=11)1.27 ± 1.35
Change at Week 12 (n=10)0.50 ± 2.27
Change at Week 24 (n=10)1.20 ± 3.01
Change at Week 36 (n=10)1.00 ± 1.89
Change at Week 48 (n=10)0.50 ± 1.84
Change at Week 60 (n=10)1.20 ± 5.31
Change at Week 72 (n=10)0.60 ± 3.06
Change at Week 84 (n=9)0.44 ± 1.51
Change at Week 96 (n=9)0.11 ± 1.27
Change at Week 108 (n=7)1.57 ± 5.68
Change at Week 120 (n=2)0.00 ± 1.41
Change at Completer Last Visit (n=9)-0.44 ± 1.24
Change at Early Withdrawal n=2)6.50 ± 0.71
Change at Last Visit (n=11)0.82 ± 3.03
SecondaryChange From Baseline in SJC

For SJC, a total of 28 joints were assessed. The presence of a swollen joint was scored as 1 and absence as 0. Total score is calculated by adding the scores, which is ranging from 0 (best possible score or no swollen joint) to 28 (worse possible score or all swollen joints). Lower scores indicate no swollen joint and higher scores indicate worsening swollen joints. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

Time frame:
Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Reported as:
Mean · Swollen Joints
Change From Baseline in SJC
Swollen JointsTocilizumab
Baseline (n=11)1.00 ± 1.67
Change at Week 12 (n=10)0.50 ± 2.37
Change at Week 24 (n=10)-0.50 ± 1.84
Change at Week 36 (n=10)-0.60 ± 2.22
Change at Week 48 (n=10)-0.80 ± 1.75
Change at Week 60 (n=10)-0.70 ± 1.49
Change at Week 72 (n=10)-0.30 ± 2.31
Change at Week 84 (n=9)-0.78 ± 1.09
Change at Week 96 (n=9)-0.67 ± 1.41
Change at Week 108 (n=7)0.14 ± 2.48
Change at Week 120 (n=2)-0.50 ± 0.71
Change at Completer Last Visit (n=9)-0.56 ± 2.24
Change at Early Withdrawal (n=2)3.5 ± 2.12
Change at Last Visit (n=11)0.18 ± 2.68
SecondaryPercentage of Participants With Clinical Remission

Clinical remission defined as:DAS28-ESR score \< 2.6 and/or SDAI score \</= 3.3.DAS28 score is measure of subject's disease activity calculated using TJC \[28 joints\],SJC \[28 joints\],PtGA of disease activity \[ VAS:0mm= no disease activity to 100 mm=maximum disease activity\] and ESR (mm/hr). DAS28 was calculated as DAS28-ESR = 0.56\*sqrt (TJC28) + 0.28\*sqrt(SJC28) + 0.70\* ln ESR + 0.014\*PtGA of disease activity. DAS28-ESR score ranged from 0 to approximately 10, higher score indicating more severe disease activity. SDAI was calculated =\[SJC (28 joints) + TJC (28 joints) + VAS PtGA + VAS physician global assessment of disease activity+CRP level(mg/dL)\]. VAS assessments:0 mm=no disease activity to 100 mm=maximum disease activity. SDAI score ranged from 0 to 86, with higher scores indicating increased disease activity.

Time frame:
Week 48, 108
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Remission
Percentage of participantsTocilizumab
Week 48 (n=10)90
Week 108 (n=8)75
SecondaryPercentage of Participants With Concomitant Corticosteroid Discontinuation
Time frame:
Baseline up to approximately 142 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Concomitant Corticosteroid Discontinuation
Percentage of participantsTocilizumab
Percentage of Participants With Concomitant Corticosteroid Discontinuation16.7
SecondaryPercentage of Participants With Concomitant Corticosteroid Dose Reduction
Time frame:
Baseline up to approximately 142 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Concomitant Corticosteroid Dose Reduction
Percentage of participantsTocilizumab
Percentage of Participants With Concomitant Corticosteroid Dose Reduction50
SecondaryTime to Concomitant Corticosteroid Discontinuation

Time to corticosteroid discontinuation = (End date of corticosteroid treatment - date of first drug intake of this extension study) + 1.

Time frame:
Baseline up to approximately 142 weeks
Reported as:
Median · Days
Time to Concomitant Corticosteroid Discontinuation
DaysTocilizumab
Time to Concomitant Corticosteroid Discontinuation472.00
SecondaryTime to Concomitant Corticosteroid Dose Reduction

Time to corticosteroid dose reduction (days) = (Date of the first dose reduction of corticosteroid treatment - date of first drug intake of this extension study) + 1.

Time frame:
Baseline up to approximately 142 weeks
Reported as:
Median · Days
Time to Concomitant Corticosteroid Dose Reduction
DaysTocilizumab
Time to Concomitant Corticosteroid Dose Reduction75 (15.0 to 758.0)
SecondaryChange From Baseline in PtGA of Disease Activity

PtGA of disease activity over the previous 24 hours using a 100 mm VAS where left end of the line 0 mm =no disease activity and right end of the line 100 mm =maximum disease activity. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

Time frame:
Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Reported as:
Mean · mm
Change From Baseline in PtGA of Disease Activity
mmTocilizumab
Baseline (n=11)17.55 ± 21.06
Change at Week 12 (n=11)11.82 ± 36.19
Change at Week 24 (n=10)4.00 ± 12.54
Change at Week 36 (n=10)0.90 ± 26.82
Change at Week 48 (n=9)-4.89 ± 14.16
Change at Week 60 (n=9)-0.89 ± 20.75
Change at Week 72 (n=9)-4.44 ± 17.54
Change at Week 84 (n=9)0.22 ± 16.17
Change at Week 96 (n=9)-3.11 ± 16.51
Change at Week 108 (n=7)-5.00 ± 24.21
Change at Week 120 (n=2)-21.50 ± 23.33
Change at Completer last visit (n=8)-6.38 ± 14.48
Change at Early withdrawal (n=2)34.00 ± 15.56
Change at Last visit (n=10)1.70 ± 21.90
SecondaryChange From Baseline in Patient's Assessment of Pain

Patient's assessment of pain over the previous 24 hours: using a VAS, left end of the line 0 mm=no pain to right end of the line 100 mm=unbearable pain. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

Time frame:
Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Reported as:
Mean · mm
Change From Baseline in Patient's Assessment of Pain
mmTocilizumab
Baseline (n=11)19.18 ± 20.58
Change at Week 12 (n=11)10.91 ± 36.68
Change at Week 24 (n=10)3.80 ± 14.99
Change at Week 36 (n=10)-1.90 ± 20.00
Change at Week 48 (n=9)-6.44 ± 11.57
Change at Week 60 (n=9)-3.78 ± 15.63
Change at Week 72 (n=9)-8.11 ± 16.56
Change at Week 84 (n=9)0.11 ± 14.44
Change at Week 96 (n=9)-8.22 ± 13.22
Change at Week 108 (n=7)-7.86 ± 18.21
Change at Week 120 (n=2)-20.00 ± 26.87
Change at Completer last visit (n=8)1.50 ± 29.71
Change at Early withdrawal (n=2)34.50 ± 16.26
Change at Last visit (n=10)8.10 ± 30.16
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score

The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

Time frame:
Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Reported as:
Mean · Units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score
Units on a scaleTocilizumab
Baseline (n=7)0.77 ± 0.55
Change at Week 12 (n=7)-0.20 ± 0.52
Change at Week 24 (n=7)0.18 ± 0.24
Change at Week 36 (n=7)-0.07 ± 0.31
Change at Week 48 (n=7)0.00 ± 0.54
Change at Week 60 (n=7)-0.13 ± 0.35
Change at Week 72 (n=6)-0.25 ± 0.41
Change at Week 84 (n=5)-0.18 ± 0.62
Change at Week 96 (n=5)0.08 ± 0.07
Change at Week 108 (n=5)-0.15 ± 0.57
Change at Week 120 (n=1)0.00 ± NA
Change at Completer Last Visit (n=6)0.10 ± 0.43
Change at Early Withdrawal (n=1)0.00 ± NA
Change at Last Visit (n=7)0.09 ± 0.39
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity

The Physician's Global Assessment of disease activity was assessed using a 0 to 100 mm horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity". Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

Time frame:
Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Reported as:
Mean · mm
Change From Baseline in Physician's Global Assessment of Disease Activity
mmTocilizumab
Baseline (n=10)11.00 ± 10.84
Change at Week 12 (n=10)17.60 ± 31.71
Change at Week 24 (n=9)5.22 ± 12.37
Change at Week 36 (n=9)2.22 ± 17.23
Change at Week 48 (n=9)-4.11 ± 7.10
Change at Week 60 (n=8)-2.13 ± 6.06
Change at Week 72 (n=8)-0.75 ± 7.87
Change at Week 84 (n=9)1.22 ± 9.80
Change at Week 96 (n=8)2.00 ± 19.25
Change at Week 108 (n=7)1.00 ± 6.90
Change at Week 120 (n=2)2.5 ± 7.78
Change at Completer last visit (n=7)6.71 ± 13.0
Change at Early withdrawal (n=2)36.5 ± 10.61
Change at Last visit (n=9)13.33 ± 17.70
SecondaryChange From Baseline in ESR

Blood samples were collected for ESR, which is an acute phase reactant and provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeters per hour (mm/hr). A decrease in the level indicates reduction in inflammation and therefore improvement. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

Time frame:
Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Reported as:
Mean · mm/hr
Change From Baseline in ESR
mm/hrTocilizumab
Baseline (n=11)5.82 ± 7.26
Change at Week 12 (n=9)-2.44 ± 8.34
Change at Week 24 (n=9)-3.11 ± 8.30
Change at Week 36 (n=9)1.89 ± 17.22
Change at Week 48 (n=10)0.90 ± 10.21
Change at Week 60 (n=10)-0.10 ± 12.64
Change at Week 72 (n=10)-2.60 ± 7.66
Change at Week 84 (n=10)2.80 ± 11.82
Change at Week 96 (n=9)-1.22 ± 9.97
Change at Week 108 (n=7)3.29 ± 21.34
Change at Week 120 (n=2)-0.50 ± 0.71
Change at Completer last visit (n=9)2.22 ± 6.55
Change at Early withdrawal (n=2)14.00 ± 15.56
Change at Last visit (n=11)4.36 ± 9.01
SecondaryChange From Baseline in CRP

Blood samples were collected for CRP, which is an acute phase reactant and a measure of inflammation. Completer last visit: Last visit data for participants who completed the study. Last visit: Last visit data for all participants (including those who discontinued prematurely). Early withdrawal: Data at the time of early withdrawal for those participants who discontinued prematurely.

Time frame:
Baseline (Day 0), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, completer last visit (up to Week 120), last visit (up to Week 120), early withdrawal (up to Week 120)
Reported as:
Mean · milligrams per liter (mg/L)
Change From Baseline in CRP
milligrams per liter (mg/L)Tocilizumab
Baseline (n=5)0.49 ± 0.47
Change at Week 12 (n=5)1.07 ± 2.17
Change at Week 24 (n=2)-0.25 ± 0.35
Change at Week 36 (n=3)-0.02 ± 0.52
Change at Week 48 (n=3)-0.05 ± 0.65
Change at Week 60 (n=3)-0.09 ± 0.66
Change at Week 72 (n=3)-0.05 ± 0.61
Change at Week 84 (n=3)-0.05 ± 0.51
Change at Week 96 (n=3)-0.02 ± 0.62
Change at Week 108 (n=3)1.55 ± 2.13
Change at Week 120 (n=0)NA ± NA
Change at Completer last visit (n=3)0.01 ± 0.54
change at Early withdrawal (n=1)4.79 ± NA
Change at Last visit (n=4)1.21 ± 2.43

Adverse events

Collected over Baseline up to approximately 142 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—2/11 (18.2%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventTocilizumab
OsteonecrosisMusculoskeletal and connective tissue disorders1/11
Inflammatory pseudotumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/11
Extremity necrosisVascular disorders1/11
Most frequent other events
Showing 10 of 43
Most frequent other events
EventTocilizumab
BronchitisInfections and infestations5/11
ArthralgiaMusculoskeletal and connective tissue disorders4/11
Urinary tract infectionInfections and infestations3/11
NasopharyngitisInfections and infestations2/11
RhinitisInfections and infestations2/11
SinusitisInfections and infestations2/11
Muscle spasmsMusculoskeletal and connective tissue disorders2/11
GastroenteritisInfections and infestations1/11
InfluenzaInfections and infestations1/11
Oral herpesInfections and infestations1/11

Baseline characteristics

Safety population included all participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean63.91 ± 11.96
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female7
Male4
08

Study locations

6 sites
  • Bordeaux, 33076, France
  • Montpellier, 34295, France
  • Nantes, 44035, France
  • Paris, 75679, France
  • Strasbourg, 67098, France
  • Toulouse, 31059, France
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2012
First posted
Nov 28, 2012
Start
Oct 2012
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Nov 28, 2016
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01734993
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 28, 2012
Start date
Oct 2012
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Nov 28, 2016
Last update
Nov 28, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion